BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

Current stock price

24.8 EUR
-0.1 (-0.4%)
Last:

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • In the past year BLC was profitable.
  • BLC had a positive operating cash flow in the past year.
  • BLC had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years BLC had a positive operating cash flow.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • BLC has a Return On Assets of 5.07%. This is amongst the best in the industry. BLC outperforms 85.71% of its industry peers.
  • With an excellent Return On Equity value of 28.66%, BLC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 6.83%, BLC is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 6.23%.
  • The last Return On Invested Capital (6.83%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROIC 6.83%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 6.19%, BLC belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BLC has declined.
  • With a decent Operating Margin value of 8.05%, BLC is doing good in the industry, outperforming 67.86% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
  • BLC has a better Gross Margin (67.32%) than 75.00% of its industry peers.
  • In the last couple of years the Gross Margin of BLC has grown nicely.
Industry RankSector Rank
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BLC.PA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BLC is still creating some value.
  • Compared to 1 year ago, BLC has about the same amount of shares outstanding.
  • Compared to 5 years ago, BLC has about the same amount of shares outstanding.
  • BLC has a better debt/assets ratio than last year.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.54, we must say that BLC is in the distress zone and has some risk of bankruptcy.
  • BLC has a Altman-Z score (1.54) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of BLC is 14.03, which is on the high side as it means it would take BLC, 14.03 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BLC (14.03) is worse than 64.29% of its industry peers.
  • A Debt/Equity ratio of 2.95 is on the high side and indicates that BLC has dependencies on debt financing.
  • BLC's Debt to Equity ratio of 2.95 is on the low side compared to the rest of the industry. BLC is outperformed by 78.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Altman-Z 1.54
ROIC/WACC1.31
WACC5.2%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • BLC has a Current Ratio of 1.16. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • BLC has a Current ratio (1.16) which is in line with its industry peers.
  • A Quick Ratio of 0.92 indicates that BLC may have some problems paying its short term obligations.
  • With a decent Quick ratio value of 0.92, BLC is doing good in the industry, outperforming 60.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.92
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1718.18% over the past year.
  • Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
  • BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 0.77%.
  • The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.90% on average over the next years.
  • Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

6

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 6.20 indicates a rather cheap valuation of BLC.
  • BLC's Price/Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 100.00% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.47. BLC is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 12.10, which indicates a correct valuation of BLC.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BLC indicates a somewhat cheap valuation: BLC is cheaper than 67.86% of the companies listed in the same industry.
  • BLC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.62, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.2
Fwd PE 12.1
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 92.86% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BLC indicates a somewhat cheap valuation: BLC is cheaper than 64.29% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.91
EV/EBITDA 4.95
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • BLC has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • BLC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (4/24/2026, 5:25:34 PM)

24.8

-0.1 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-18
Earnings (Next)05-14
Inst Owners12.78%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap182.78M
Revenue(TTM)476.02M
Net Income(TTM)29.45M
Analysts77.14
Price Target40.8 (64.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP0.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.68%
PT rev (3m)12.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-8.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 6.2
Fwd PE 12.1
P/S 0.38
P/FCF 7.91
P/OCF 2.53
P/B 1.78
P/tB N/A
EV/EBITDA 4.95
EPS(TTM)4
EY16.13%
EPS(NY)2.05
Fwd EY8.26%
FCF(TTM)3.13
FCFY12.64%
OCF(TTM)9.79
OCFY39.48%
SpS64.59
BVpS13.94
TBVpS-12.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.4217 (42.83%)
Profitability
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROCE 9.29%
ROIC 6.83%
ROICexc 7.28%
ROICexgc 14.48%
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
FCFM 4.85%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Debt/EBITDA 3.11
Cap/Depr 83.01%
Cap/Sales 10.3%
Interest Coverage 250
Cash Conversion 74.08%
Profit Quality 78.46%
Current Ratio 1.16
Quick Ratio 0.92
Altman-Z 1.54
F-Score7
WACC5.2%
ROIC/WACC1.31
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y3.06%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y-31.71%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y-17.98%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 5 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 6 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


What is the profitability of BLC stock?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for BLC stock?

The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 6.2 and the Price/Book (PB) ratio is 1.78.


Can you provide the financial health for BLC stock?

The financial health rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 3 / 10.